pharmaphorum

NOVEMBER 24, 2022

The phase 3 ESCAPE-TRD study in 676 patients revealed that significantly more of those treated with Spravato were able to achieve remission from symptoms of depression without a relapse over 32 weeks of follow-up compared to quetiapine. and 17.6%, respectively, according to J&J’s pharma unit Janssen. and 14.1%, respectively.

Sales 52

Sales Patients Competition Marketing 52

Pharmaceutical Technology

FEBRUARY 3, 2023

Based on GlobalData’s patient-based forecast models, RA and CD are the top two indications contributing to this value, accounting for around 45% and 14%, respectively, of Humira’s sales. According to GlobalData’s Sales and Forecast Consensus database, Humira is anticipated to have garnered sales of $18.6 billion in 2022.

Marketing 52

Marketing Sales Patients Physicians 52

Pharmaceutical Technology

APRIL 4, 2023

of NSCLC patients with exon 19 and 21 mutations develop resistance mutations at C797S. According to GlobalData’s Pharma Intelligence Centre, Tagrisso is forecasted to have global sales of $8.19 billion in 2029. Up to 12.5% While Scorpion will lead the development of STX-721, Pierre Fabre will handle STX-241.

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52

Pharmaceutical Technology

JULY 15, 2022

Most of the US insulin market is controlled by three pharma companies: Sanofi, Eli Lilly, and Novo Nordisk. Type 1 diabetes (T1D) is forecast to affect five million people in the eight major pharmaceutical markets, which are the US, France, Germany, Italy, Spain, UK, Japan, and Canada, by 2029.

Manufacturing 131

Manufacturing Insurance Pharmaceutical Marketing 131

World of DTC Marketing

AUGUST 7, 2022

The passage of the Inflation Control bill is an excellent first step in limiting high drug costs, but our healthcare system is still built for profit at the expense of patients. Patients and doctors are tired, and insurance companies are raising rates after two years of making a surplus because nobody went to the doctor during the pandemic.

Insurance 263

Insurance Doctors Government Physicians 263

European Pharmaceutical Review

JANUARY 18, 2024

The company predicted this will be “driven by an increase in the patient share of dual orexin receptor antagonists (DORAs)”. In the US in 2029 and in Japan in 2031, Belsomra is set to lose market exclusivity. percent from $3.2 billion in 2022 to $4.1 billion in 2032. percent between 2022 and 2032. million in sales by 2032.

Marketing 88

Marketing Sales Pharmacology Pharma 88

European Pharmaceutical Review

JUNE 16, 2023

According to Maximize Market Research , new technologies are expected to boost the clinical trials market between 2022 to 2029, especially as the industry and patients are shifting towards digitalisation approaches and personalised medicines.

Safety 98

Safety Electronics Recruitment Medical 98

Pharmaceutical Technology

MAY 17, 2023

Orphan drug designations are granted to drugs that target rare disorders with fewer than 200,000 patients in the US. Primary biliary cholangitis is a rare autoimmune disease where small bile ducts are injured by the patient’s own immune system. billion in 2029. This results in bile buildup in the liver and can lead to scarring.

Food and Drug Administration 52

Food and Drug Administration FDA Pharmaceutical Prospecting 52